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Abstract: Medicinal plants have widely been used in the
traditional treatment of ailments and have been proven
effective. Their contribution still holds an important place in
modern drug discovery due to their chemical, and bio-
logical diversities. However, the poor documentation of
traditional medicine, in developing African countries for
instance, can lead to the loss of knowledge related to such
practices. In this study, we present the Eastern Africa
Natural Products Database (EANPDB) containing the struc-
tural and bioactivity information of 1870 unique molecules
isolated from about 300 source species from the Eastern
African region. This represents the largest collection of
natural products (NPs) from this geographical region, cover-
ing literature data of the period from 1962 to 2019. The
computed physicochemical properties and toxicity profiles
of each compound have been included. A comparative
analysis of some physico-chemical properties like molecular
weight, H-bond donor/acceptor, logPo/w, etc. as well scaffold
diversity analysis has been carried out with other published
NP databases. EANPDB was combined with the previously
published Northern African Natural Products Database
(NANPDB), to form a merger African Natural Products
Database (ANPDB), containing ~6500 unique molecules
isolated from about 1000 source species (freely available at
http://african-compounds.org). As a case study, latrunculins
A and B isolated from the sponge Negombata magnifica
(Podospongiidae) with previously reported antitumour
activities, were identified via substructure searching as
molecules to be explored as putative binders of histone
deacetylases (HDACs).
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1 Introduction
Historically, natural products (NPs), i. e. compounds derived
from natural sources (bacterial, fungi, plants or animal
species) possessing biological activities; have been the
primary provenance of medicine globally.[1] Although the
approval rate of new drugs from nature has not increased
proportionally with the financial and technological invest-
ments on NP researches,[2] NPs still account for about half of
the FDA-approved drugs..[2a,d,3] Thus, seeing the remarkable
contribution of NPs as drugs, huge amounts of NPs are
being isolated and characterized daily. Also, the biological
evaluations of the isolated molecules are carried out in
order to confirm the therapeutic claims. Further studies on
the establishment of the mechanisms of actions of the
isolated biologically interesting NPs are being carried out
with the hope of getting the next generation lead
compounds for drug discovery.[4]
One of the magnificent beauties of the African continent
is its richness in flora and fauna. This richness offers the
African population diverse traditional means in treating
ailments based on what nature has presented to them.
However, due to poor documentation, some of this tradi-
tional information is being lost nowadays. This is one of the
main factors behind the scientific exploration of the known
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traditional methods as well as the source species (bacteria,
fungi, plants or animals). Accordingly, several NPs have
been identified and collected into several public and
commercial databases and repositories.[4g,5,6a] However, anal-
ysis, e.g. by using principal component analysis (PCA) of the
available NP datasets show that only a small portion of the
already annotated NPs originate from Africa or even
occupying similar chemical space to the current collection
of African NPs.[6]
Many of the medicinal plants from the Eastern African
region have illustrated interesting values in traditional
medicine, which makes use of indigenous knowledge to
treat diseases.[7] This paper describes a collection of 1870
NPs from 302 species belonging to 58 families (some having
usage in traditional medicine), with data coverage from
1962 to 2019, as well as a pharmacoinformatic analysis of
the compound data. This novel electronic dataset, called
East African Natural Products Database (EANPDB) provides
interesting information regarding the original literature
sources and currently stands out as the largest collection of
NPs from Eastern Africa. The molecular structures and
metadata of EANPDB are accessible as supplementary files
to this article. Furthermore, EANPDB was combined to the
previously published Northern African Natural Products
Database (NANPDB),[6c] to form a merger called the African
Natural Products Database (ANPDB), which is freely avail-
able at http://african-compounds.org. The combined data-
set resulted in ~6500 unique molecules.
2 Methods
2.1 Data Curation
The data was collected as part of our ongoing project,
which is the development of chemical libraries of natural
products from African medicinal plants, marine, fungal and
bacterial sources.[6b,c,e,f] The unified ANPDB is constantly
being updated based on inputs from journal articles and
MSc/PhD. thesis from African university libraries of various
regions. In the current study, emphasis was laid on data
published on compounds identified from source species
harvested in the Eastern African region (including the
countries; Burundi, Ethiopia, Kenya, Rwanda, Tanzania,
Uganda). The data for the source species, compounds,
literature references and the use of the plant species were
compiled on spreadsheets, following our previously de-
scribed methodology.[6c] Chemical structures currently avail-
able in PubChem[8] were exported as SDF files, while
structures unavailable in PubChem were sketched as MOL
files using ChemDraw software (Prime version 16, courtesy
Perkin Elmer). SMILES strings were generated using
OpenBabel.[9]
2.2 Dataset Preparation
Data preparation was mainly done using PostgreSQL tables,
as described in our previous publication.[6c] Generally,
compound and source species information were carefully
and manually retrieved and double checked. For example, a
Python API was used to retrieve individual molecules with
appropriate PubChem Compound ID (CID) as 2D SDF files
alongside compound names and synonyms if present in
PubChem.[8] Additionally, the 2D MOL files for molecules
not found in PubChem or ChemSpider[10] (based on
searches using the name from literature and canonical
SMILES) were manually sketched using ChemDraw (Prime
version 16, Perkin Elmer) based on the published 2D
structures as in the referenced literature source, while
comparing with data available in Scifinder.[11] Furthermore,
all SMILES were canonicalized with OpenBabel.[6c,12] During
this process, a unique InChI (the identifier of molecular
global uniqueness) was assigned to each unique canonical
SMILES.[12c] For each molecule of the EANPDB, both the
inchified SMILES and the corresponding InChI are provided
on our online platform.
2.3 PAINS Analysis of EANPDB Content
The presence of certain structural features referred to as
pan-assay interference compounds (PAINS) have been
established to certain behaviours (such as metal chelation,
redox cycling and protein reactivity). that could interfere in
assay readouts all the way from target to cell without any
common mechanism involved. The compounds of EANPDB
were screened to estimate the proportion of molecules that
are predicted to be PAINS. PAINS analysis was performed
using PAINS1, PAINS2, and PAINS3 filters, as implemented
in Schrödinger’s Canvas program.[13]
2.4 Diversity Analysis using Principal Components
Searching for novel compounds from a different chemical
space with significant biological importance is currently
vital in the field of drug discovery. This could be one
approach towards facing the challenges of drug resistance.
It is believed that such molecules could act via a different
mechanism.[14] In order to evaluate in the chemical space
occupancy of the different datasets, a PCA using the MOE
package was performed.[15] Several selected descriptors
were computed and transformed linearly using PCA to
obtain a new and smaller uncorrelated and normalized
table of descriptors (mean=0 and variance=1).[16] The
descriptors for this purpose included the number of donor/
accptHB, number of heavy atoms present, the number
rotatable bonds, calculated molecular weight, predicted
molar refractivity, the predicted total polar surface area and
the computed octanol/water partition coefficient. Percent-
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age variation based on counts as well as 2- and 3-
dimensional plots of PCA1, PCA2 and PCA3 (the best three
principal components) were used to depict the diversity of
molecules.
2.5 Scaffold Diversity Analysis
In the field of small-molecule drug discovery, scaffold
novelty/diversity is an important issue for complicated
(hard to treat) ailments.[17] Chemical scaffolds have diverse
usages and play a key role in lead compound
identification.[18] In order to evaluate the scaffold diversity
within the published NP datasets from Africa, scaffolds for
the unique molecules found in the EANPDB were analyzed
in comparison to those of the updated NANPDB using the
Platform for Unified Molecular Analysis (PUMA) platform.[19]
This platform makes use of integrated metrics to character-
ize compound databases including the visualization of
scaffold content, fingerprint diversity among others from
the user input file (a comma-separated value (.csv) file
having three columns; SMILES, database names, and
compound IDs). In this study, both the Cyclic System
Recovery (CSR)[20] and Scaled Shannon Entropy (SSE)[21] were
used to analyse the scaffold of molecules having at least a
ring system while ignoring molecules with no ring. In this
work, the cyclic systems were defined after the iterative
removal of all side chains of the molecule.
2.6 Drug-likeness and DMPK Prediction
Unique SMILES were used to generate the 3D models as
well as the calculation of drug metabolism and pharmaco-
kinetics (DMPK) properties of the collected molecules in our
dataset using LigPrep and QikProp packages, respectively,
of the Schrodinger software, as previously described.[22]
Some of the computed properties of interest included
molecular weight (mol_MW), the number of H-bonds that
would be donated/accepted by the solute to water
molecules in an aqueous solution (donor/accptHB), the
number of non-trivial (not CX3), non-hindered (not alkene,
amide, small ring) rotatable bonds (#rotor), the computed
octanol/water partition coefficient (QPlogPo/w), predicted
IC50 value for the blockage of HERG potassium ion (K
+)
channels (QPlogHERG), predicted brain/blood partition co-
efficient (QPlogBB), predicted skin permeability (QPlogKp),
the number of likely metabolic reactions (#metab), predic-
tion of binding to human serum albumin (QPlogKhsa), the
number of violations of Lipinski’s “rule of five” (RuleOfFive)
and the number of violations of Jorgensen’s rule of three
(RuleOfThree).
2.7 Toxicity prediction
In a similar protocol.,[6c] in silico prediction of the toxicity
was carried out on the freely accessible online pkCSM web
server (Cambridge University) for all the EANPDB
molecules.[23] The pkCSM platform provides a prediction of
several parameters related to absorptions, distribution,
metabolism, excretion and toxicity (ADMET), which includes
ten toxicity endpoints as seen in Table 1.
2.8 Case Study: Substructure Searching
Post-translational modification of histone proteins by
enzymes such as histone deacetylases (HDACs, which
catalyse the deacetylation of lysine residues on histone
tails) participate in several physiological processes and are
considered potential drug targets for various diseases.[24]
Human HDACs are represented in eighteen isoforms which
are grouped as zinc-dependent (Classes I, II and IV) or NAD+
-dependent (Class III).[25] The zinc-dependent HDACs com-
prise of the following isoforms; class I (HDAC1-3, HDAC8),
class II (IIa: HDAC4-5, HDAC7, HDAC9 and IIb: HDAC6,
HDAC10) and class IV (HDAC11). Resolved crystal structures
show that the catalytic domain is conserved. Interest in
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prediction will determine if a molecule is an hERG I or hERG II
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targeting these HDAC isoforms have led to the market
approval of several HDAC inhibitors and more are inten-
sively being developed.[24a,b, f] However, because of the
conserved nature of the binding pocket, most inhibitors
lack selectivity between the various HDAC isoforms.[24a,b]
Thus, there is a need to search for novel HDAC inhibitors
that can achieve selectivity among the structurally similar
HDAC isoforms.
A classical pharmacophore model for HDAC inhibitors as
proposed by Jung et al.[26] consists of three features; a zinc-
binding group (ZBG) coordinating the catalytic zinc ion, a
linker placed in the hydrophobic substrate-binding tunnel
and the capping group (cap) that interacts with the rim of
the pocket. An attempt to search for novel and selective
HDAC inhibitors has been to search for a new ZBG that can
make a significant contribution to the binding affinity.
Amongst the reported HDAC inhibitors from nature are the
macrocyclics; romidepsin and largazole, having a thiol ZBG
in their activated forms.[27] In this regard, substructure
searching,[24g] which represents a simple but powerful tool
in drug discovery to perform initial filtration of molecules
implemented in our online database was used to search for
molecules with a thiol group, sulphur containing ZBG or
sulphur-containing molecules that can also be activated to
HDAC inhibitors.
3 Results and Discussion
3.1 Overview of Data
This study provides a simple to use and interactive online
platform containing data for isolated NPs from sources of
East African origin. For the sake of preserving the knowl-
edge of the traditional application of medicinal plants in
this region of Africa, this comprehensive database was
developed via the manual curation of literature sources.
The entire content of this database (which includes:
information about source species and country of harvest,
isolated molecules, reported biolocigal activity, predicted
drug-likeness properties amongst others) can be accessed
and downloaded from http://african-compounds.org The
current release of EANPDB is summarized in Table 2 below.
This includes information from 315 citable literature
sources, of which less than half of this material could be
found in PubMed, with only 154 references having PubMed
IDs (PMIDs).
Approximately 40% of the molecules had no PubChem
ID (CID). Additionally, >500 of the molecules at the time of
isolation and characterization were being reported for the
first time. Giving the chance, several other new molecules
can still be isolated from some of the less explored plant
families (Figure 1). We observed a total of 70 compound
classes, with the major contributors being terpenoids,
flavonoids, quinones, alkaloids and phenolics (summing up
to >80% of all the molecules currently in EANPDB,
Figure 2).
Interestingly, this trend of the top compound class
occupiers is very similar to what was observed in the
Northern African NP database.[6c] Additionally, about 44% of
the molecules in the EANPDB have at least one reported
biological activity from a broad list of activities curated
from the literature. These reported activities have been
grouped into 40 classes. Anti-malarial/anti-plasmodial eval-
uations were the most reported (Figure 3). This is following
the fact that malaria and other parasitic diseases remain
serious burdens to the people in this region.[28] Thus, the
scientific validation of most of the traditional application of
medicinal plants goes into confirming the usage of such
plants in treating parasitic diseases such as plasmodial
related ailments. Also, a few molecules from East African
sources with interesting anti-viral (HCV and HIV) activities
were reported and are present in this version of the
database. To further validate some of the reported activities,
mechanism of action (MOA) for 3 of the molecules have
been confirmed and has been curated in the EANPDB.
These molecules include nitidine (1), synaptolepis factor K7
(2) and kirkinine (3) (Figure 4).[29–31]
Nitidine (1) was isolated by Rashid et al., from Toddalia
asiatica (Rutaceae); a plant used traditionally in several
communities in Kenya for the treatment of malaria and
other ailments.[29] Reports have it that all parts of the plant
are claimed to have medicinal values, but the roots, in
particular, are believed to be more potent.[30] This plant is
administered traditionally as decoction or infusion of the
roots for patients to drink for the treatment of malaria, fever
and to cure stomach ache. For toothache, the root is
chewed whereas for the treatment of coughs the fruits are
chewed. In the study, Rashid et al. evaluated and reported
that compound 1 is an anti-HIV-1 molecule capable of
inhibiting HIV-1 reverse transcriptase. Although this mole-
cule showed interesting anti-HIV activity, it was also
Table 2. Summarized content of the EANPDB.
Number of references 315
Number of source organisms 302
Number of unique SMILES 1870
Number of compound classes 70
Number of unique PubMed IDs 154
Number of kingdoms 3
Number of unique PubChem IDs 1115
Number of biological activities 82
Number of families 58
Numbers of compounds identified for the first time 515
Molecules with reported biological activity 815
The data included 1,870 unique compounds from 302 source
organisms from 3 kingdoms, belonging to 60 families (Figure 1). It
was observed that the major contributing families occupying
>50% of the explored source species families were Leguminosae
(Fabaceae) (~20%), Compositae (Asteraceae) (~10%), Asphodela-
ceae (~9%), Annonaceae (~8%) and Burseraceae (~6%).
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cytotoxic to the host cells at approximately 15 μg/ml.[29]
Thus, just like many other reported NPs, further optimiza-
tion of nitidine (1) could serve as a good starting point in
the development of novel and potent anti-HIV drugs.[1c,e, 2b–d,
6f] Other molecules isolated from EA source species with
reported modes of action include the daphnane diterpene
Figure 1. Bar chart showing the percentage contribution by family.
Figure 2. Distribution of main compound classes.
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esters; synaptolepis factor K7 (2) and kirkinine (3), both
reported as having anti-tumoral and neurotrophic actions,
acting via the modulation of protein kinase C.[31] These
compounds were isolated from the roots of Synaptolepis
kirkii (Thymelaeaceae), which is commonly used to manage
epilepsy and snake bite.[31] Although the evaluated activities
and proposed modes of action of the compounds 2 and 3
deviated from the local traditional usage of this plant
species, this buttresses the point that NPs from medicinal
plants have a broad spectrum/range of activities and can be
chemically modified to suit our target of interest.[1b,c, 2b, c, 3a, 6d]
In brief, this opens another corridor of scientific research
on NPs from this area, which can be focused on the
evaluation of the MOA of isolated NPs from this region,
since very little has been done in this regard. Furthermore,
PAINS investigation of the molecules present in EANPDB
revealed that only 241 molecules (~13%) had scaffolds that
could be predicted with an endpoint for the presence/
manifestation as a PAINS. The list of matching PAINS and
the number of scaffolds containing them are summarized in
Table SI_1. In a similar way as previously reported by
Baell,[32] the majority of the molecules (~95%) from our
dataset filtered as PAINS were molecules having the
catechol(s) or quinone(s) scaffolds/fragments. Based on
reports obtained from literature sources, it is confirmed that
catechols and quinones can interfere in bioassays via
different mechanisms such as metal chelation, redox
cycling, redox activity as well as covalent reaction with
biological targets and protein reactivity – which has been
attributed to some observed toxic effects.[33]
Additionally, comparative studies between EANPDB with
other compound databases (e.g. DrugBank,[34]
StreptomeDB,[12a] NANPDB[6c] and NuBBE[5e]) will be dis-
cussed.
Figure 3. Distribution of reported biological activities within the EANPDB.
Figure 4. Molecules from the EANPDB with reported mechanisms of
action (MOA).
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In a nutshell, EANPDB was combined with NANPDB to
form ANPDB and can be accessed via http://african-
compounds.org/. With ~6500 unique molecules isolated
from about 1000 source species, ANPDB represents the
most extensive collection of African NPs available at the
moment. The platform is built with an array of search fields
that can be used on the entire African collection or
narrowed down to specific regions, for example, the
EANPDB. Some of the search methods include biological
activity, compound name, source species, families and
authors/reference. Similarity search and substructure search
procedures are also implemented on our online platform.
The structural similarity search makes use of the Tanimoto
coefficient of similarity to measure the 2D similarity
between the query molecule and the database entries. This
tanimoto coefficient represents a number between 0 and 1;
with 1 being the highest and referring to an exact match.
The fingerprints used for the structural similarity search are
pre-calculated for all database entries and stored as blob
objects in the PostgreSQL-database. For each query
structure, calculations are made during the search. We also
provide users of our platform with an option to download
the entire content as 2D or 3D SDF files or SMILES.
Additionally, there is a help page to guide new users
through our platform which also answers technical ques-
tions that might arise.
3.2 Chemical Space Analysis
A diverse dataset holds a key premise for the identification
of novel molecules via screening methods when compared
to a similar-sized combinatorial library with limited struc-
tural variation.[35] To analyze the chemical space coverage of
the EANPDB, PCA in comparison with the updated versions
of NANPDB[6c] and NuBBE[5e] was performed and the findings
are presented here. The molecular diversity of the NPs
constituting the EANPDB, using PCA is illustrated with the
3D scatter plots in Figure 5.
An analysis of the three most important principal
components demonstrated that approximately 95% cova-
riation of the global information could explain the content
of the various datasets, As observed in Figure 5, the three
datasets clustered around at the centre, an indication of the
molecules occupying similar chemical space. However,
portions of each dataset tend to deviate outwardly in
different directions. Thus, an indication of molecules that
are chemically different from those represented at the
centre. As observed, the top section of the scatter plots in
the figures is highly represented by molecules from NuBBE,
while the left part of the plot is occupied more by the
EANPDB and the lower part of the figure shows an
overwhelming presence of NANPDB molecules. Thus, the
content of the EANPDB, NANPDB and NuBBE dataset
molecules used in this study are observed to occupy diverse
chemical spaces.
3.3 DMPK
A drug-likeness study to show the distribution of the
EANPDB molecules (Table 3) was further carried out using
common druglikeness filters like molecular weight (mol_
MW), logarithm of the octanol/water partition coefficient
(QPlogPo/w), number of H-bond donors (donorHB), number
of H-bond acceptors (accptHB), as well as an evaluation of
the ratio of molecules violating the lead-like rule of 3
(RuleOfThree) and the Lipinski rule of 5 (RuleOfFive) for orally
available drug molecules. The variation in terms of percen-
tages of these physicochemical properties among the
selected datasets for comparison is shown in Figures 6–8.
As observed in Figure 6A, the data indicate that the
distribution of mol_MW generally followed a Gaussian-like
curve with maximum peaks around 300 Da. While mole-
cules with mol_MW <500 Da dominated the EANPDB,
NANPDB, DrugBank and NuBBE datasets, the StreptomeDB
dataset rather demonstrated an almost level distribution in
the number of molecules with ~200 Da<mol_MW< ~
550 Da. Approximately 85% of the molecules contained in
all the datasets analyzed had MW less than 500, thus
meeting one of the Rules of Five for oral drugs. Similarly,
the distribution of molecules concerning the predicted
QPlogPo/w below 5 also dominated (~85%). All calculated
QPlogPo/w for molecules in the different datasets used in this
study for comparison followed a similar distribution pattern
(Figure 6B).
Furthermore, analysis of the count of donor/accptHB
(Figure 7) content for each of the utilized datasets showed
Table 3. Some computed QikProp descriptors. The maximum
(Max), minimum (Min) and average (Avg) values for molecules in
the EANPDB as well as the recommended range.
Descriptors Max Min Avg Recommended range
mol_MWa 1237.39 73.00 348.82 130.0–725.0
QPlogPo/w
b 17.18 -7.09 3.45   2.0–6.5
donorHBc 17.00 0.00 1.33 0.0–6.0
accptHBd 44.50 0.00 5.04 2.0–20.0
#rotore 47.00 0.00 6.04 0–15
QPlogBBf 2.43   10.13   1.05   3.0–1.2
QPlogKp
g 10.13   14.35   2.71   8.0–  1.0
QPlogHERGh -0.83   8.47   4.59 concern below   5
#metabi 0.00 20.00 4.53 1–8
TPSAj 1621.47 244.81 619.67 300.0–1000.0
QPlogSk 0.98   18.87   4.62   6.5–0.5
QPlogKhsa
l 4.11   3.15 0.33   1.5–1.5
a Molecular weight (DA), b Logarithm of the octanol/water partition
coefficient, c Number of H-bond donors, d Number of H-bond
acceptors, e Number of rotatable single bonds, f Logarithm of the
blood/brain barrier partition coefficient, g Logarithm of the skin
permeability coefficient, h Logarithm of the HERG blockage
coefficient, i Number of metabolites, j Total polar surface area, k
Logarithm of the water solubility parameter, l Logarithm of the
binding constant to human serum albumin.
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Figure 5. Chemical space analysis using the best 3 PCAs (PCA1, PCA2 and PCA3). A) Distribution of molecules in EANPDB, B) Distribution of
molecules in NANPDB, C) Distribution of molecules in NuBBE and D) Overlay of all three datasets to appreciate their spatial distribution.
Blue, Green and black balls represent EANPDB, NANPDB and NuBBE respectively.
Figure 6. Distribution of A) molecular weight and B) logP (octanol-water) coefficient for EANPDB, DrugBank, StreptomeDB, NANPDB and
NuBBE datasets.
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that about 80% of the molecules in each dataset had
respected the conditions of donor/accptHB in the rule of 5.
From the obtained donor/accptHB data, we could observe a
similar distribution for the EANPDB, NANPDB and DrugBank.
It was remarkable that approximately 42% of molecules in
the NuBBE dataset had no donorHB (Figure 7A) while the
StreptomeDB dataset, on the other hand, had about 40% of
its molecules fulfilling the required criterion for the accptHB
filter (Figure 7B). However, this difference in the observed
distribution of donor/accptHB stands to confirm the fact
that the composition and diversity of molecules from
StreptomeDB (containing NPs from Streptomyces sp.) has
not been studied systematically and quantitatively and may
vary otherwise from NPs from plant sources.
An evaluation of the computed physicochemical proper-
ties of the violation of the “Rule of Five” is summarized in
Figure 8. The molecular enumeration showed that a
majority of molecules in the EANPDB (~65%) had no
Lipinski’s (Rule of Five) violation, while approximately 85%
of all the molecules in the analyzed datasets had < = 2
Lipinski’s violation (Figure 8A). Additional investigation of
how lead-like the content of the three NPs datasets
(EANPDB, NANPDB and NuBBE; mainly from plant sources)
was performed (Figure 8B). It was observed that about 55%
of the NPs from the Northern and Eastern parts of Africa
had no lead-like (Rule of Three) violation while ~60% of the
Brazilian collection (NuBBE) had no lead-like violation.
3.4 Toxicity Prediction
The application of in silico methods such as virtual screen-
ing and toxicity prediction have continuously gained
grounds to complement resource expensive wet laboratory
experiments in the drug discovery pipeline. This is
especially the case when it comes to NPs that are normally
available only in low yields. A good proportion of the
molecules were predicted as negative (complied) with the
AMES mutagenic test in bacteria (Table 3). A negative
prediction with the AMES text indicates that the compound
in question is not mutagenic and may not act as a
carcinogen. On the other hand, almost all the molecules in
EANPDB (99.7%) were predicted as not interfering with the
inhibition of the potassium ion (K+) channels (encoded by
hERG I). About 85% of the content of the EANPDB were
predicted to have no hepatotoxic or skin sensitization
effect. The human maximum tolerated dose (Max. tolerated
dose in log mg/kg/day) extrapolated from animal data that
gives an idea of the maximum recommended starting dose
in phase I clinical trials (the toxic dose threshold of
chemicals in humans) has been predicted for each mole-
cule. The maximum (Max), minimum (Min) and Average
(Avg) of the Max. tolerated dose (human) alongside the Oral
Rat Acute Toxicity (LD50), Oral Rat Chronic Toxicity (LOAEL),
Tetrahymena pyriformis toxicity and Minnow toxicity have
been summarized in Table 4.
Figure 7. Distribution of A) H-bond donor and B) H-bond acceptor for EANPDB, DrugBank, StreptomeDB, NANPDB and NuBBE datasets.
Figure 8. Percentile violation of A) drug-likeness (Lipinski’s rule of five violation) B) lead-likeness (Jorgensen’s Rule of Three violation).
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3.5 Scaffold Analysis
Molecules with ring system(s) were used in this analysis
while those that do not have any rings were ignored.
However, we observed that molecules without a ring
system represented a very small minority of the complete
datasets and therefore should not bias the overall scaffold
analysis. The output file downloaded from the Scaffold (CSR
curves) tap in PUMA shows that there is little scaffold
diversity within the NANPDB and EANPDB (Figure 9). A
highly diverse dataset is considered to have a CSR area
under the curve (AUC) of about 0.5; an indication that there
is almost one scaffold for each compound. The downloaded
summary statistics (Tables S1; downloaded from “Download
unique scaffolds”) confirmed that most of the compounds
are cyclic (Figure 10). Both datasets have similar diversity in
terms of scaffolds with AUCs of 0.86 and 0.87 and SSE30 of
0.90 and 0.91 for EANPDB and NANPDB respectively
(Tables SI_2–4 and Figures SI_1, 2).
3.6 Identification of Latrunculins A and B from the Online
African NP Database using a Substructure Search
In order to evaluate the application of the African NP
database, we applied a substructure search for molecules
having a methylthiol moiety (chemical formula; CH3SH and
canonical SMILES; CS). The existence of several thiol based
HDAC inhibitors such as romidepsin and largazole (both
prodrugs that generate the thiol in vivo) supports our idea
to find molecules that possess sulphur containing func-
tional groups from our database that can be used as a ZBG
in the development of HDAC inhibitors (Figure 11).
A substructure search using CH3SH yielded 30 different
molecules (Figure 12), mostly derivatives of latrunculins A
and B (Figure 11). These molecules are mostly extracted
from Negombata magnifica (Podospongiidae).[36] The pre-
viously reported biological activity is antitumour activity,
with mode of action proposed as binding reversibly to actin
monomers, forming a 1 :1 complex with G-actin and
disrupting its polymerization. Interestingly, latrunculins A
and B both had no Lipinski’s violation and their toxicity
prediction showed that they can be good clinical candi-
dates. It was interesting to observe that these molecules
possess antitumour activity and possess a thiazolidin-2-on
group that might act as a ZBG or may be activated to
function as HDAC inhibitors. Moreover, HDACs have been
reported to be new and interesting drug targets in the
search of novel cancer/tumour related drugs.[24e,37] It is left
to question whether these molecules are inhibitors of
Table 4. Some of the toxicity prediction endpoints. The maximum
(Max), minimum (Min) and average (Avg) values for molecules in
the EANPDB, along with the recommended range.




2.35   2.97 0.17 < =0.477
Oral Rat Acute
Toxicity (LD50)
4.78 1.10 2.38 ***
Oral Rat Chronic
Toxicity (LOAEL)
11.94   0.80 2.02 ***
Tetrahymena
pyriformis toxicity
2.59   1.86 0.49 < =0.5
Minnow toxicity 22.99   11.28 0.98 >0.3
*** Interpreted relative to the bioactive concentration and
treatment length.
Figure 9. Distribution of scaffold similarity between EANPDB and NANPDB using A) CSR and B) SSE30.
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HDACs as another unexplored or not reported mode of
action.
4 Conclusions
NPs, especially those from African sources deserve more
attention as they have been proven to be underrepre-
Figure 10. Display of most frequent cyclic scaffolds.
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sented, unexplored and understudied for drug discovery.
NPs have been reported to contribute strategically in the
drug discovery process either as new drug molecules or the
relevant scaffold for the synthesis of novel bioactive
molecules. In this study, we are continuing our effort to
provide an online free database of NPs from African
sources.[6b,c–g] The current collection herein represents the
most comprehensive collection of NPs from the Eastern
Africa region covering the period 1962 to 2019. This
collection contains relevant details such as possible modes
of action, as well as predicted toxicity, compound SMILES,
3D models computed physico-chemical properties to
estimate pharmacokinetics and pharmacodynamic proper-
ties, and literature reference of source data. It was shown
that a significant portion of the molecules is not annotated
in the PubChem database as well as the relatively few
references found in PubMed. Additionally, just like the well-
known NP databases, comparative studies indicated that
the EANPDB can be a good starting point for virtual
screening based on the DMPK and Toxicity predictions
made. Substructure searching starting from the methylthiol
group (as a case study) for the identification of new HDAC
inhibitors yielded molecules that were mostly latrunculins A
and B derivatives. Latrunculins A and B have been reported
to possess antitumour activity and in silico evaluation of
these molecules show typical characteristics of good drug
candidates.
Supporting Information Available
Details on EANPDB content, molecular structures and their
sources of the collection as well as computed descriptors
can be accessed free of charge via the Internet at http://
african-compounds.org. The metadata is also available as
additional spreadsheets.
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